# Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

> **NCT05549661** · PHASE1 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 25 (estimated)

## Conditions studied

- Recurrent Chronic Myelomonocytic Leukemia
- Refractory Chronic Myelomonocytic Leukemia
- Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
- Recurrent Atypical Chronic Myeloid Leukemia
- Recurrent Myelodysplastic/Myeloproliferative Neoplasm
- Refractory Myelodysplastic/Myeloproliferative Neoplasm

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration and Biopsy
- **DRUG:** Onvansertib
- **PROCEDURE:** Ultrasound Imaging

## Key facts

- **NCT ID:** NCT05549661
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-04
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05549661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05549661, "Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05549661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*